Digital Therapeutics Market in U.S. Like to Reach $5.08 Billion by 2027 at 19.2% CAGR

U.S. Digital Therapeutics Market

U.S. Digital Therapeutics Market

Rise in adoption of smart wearables with healthcare apps and surge in need to curb healthcare costs drive the growth of the U.S. digital therapeutics market

PORTLAND, OR , UNITED STATES, September 30, 2020 / — Allied Market Research published a report, titled, "U.S. Digital Therapeutics Market by Application (Diabetes, Obesity, Cardiovascular Disease (CVD), Central Nervous System (CNS) Disease, Respiratory Disease, Smoking Cessation, Gastrointestinal Disorder (GID), and Others), Product (Software and Device), and Sales Channel (Business-to-Business(B2B), Business-to-Consumer (B2C)): Opportunity Analysis and Industry Forecast, 2020–2027." According to the report, the U.S. digital therapeutics industry generated $1.16 billion in 2019, and is estimated to generate $5.08 billion by 2027, growing at a CAGR of 19.2% from 2020 to 2027.

Download Sample Report with Detailed COVID-19 Impact Analysis at:

Drivers, restraints, and opportunities

Rise in adoption of tablets, smartphones, and smart wearables along with healthcare apps, surge in need to curb healthcare costs, and adoption of technologically advanced healthcare products & applications drive the growth of the U.S. digital therapeutics market. However, data privacy concerns and lack of proper reimbursement policies restrain the market growth. On the other hand, supportive laws and regulations for digital health technologies and surge in investments from market players create new opportunities in the coming years.

COVID-19 Scenario

There has been rise in awareness regarding digital health, avoidance of physical visits to clinics to reduce possibility of infection, and increase in mental health issues raised demand for digital therapeutics during the Covid-19 pandemic.
Digital therapeutics startups and leading players have been addressing conditions such as Type 2 diabetes, addiction, autism, and musculoskeletal injuries through video consultations, releasing instructional videos and blogs on their websites, and distributing healthcare programs through apps.
After receiving medications and treatments remotely, people have been ordering medication and medical devices through online channels.
"U.S. healthcare embraces digital therapeutics under the pressure of COVID-19 pandemic"

The diabetes segment to maintain its dominant position throughout the forecast period

Based on application, the diabetes segment held the highest market share in 2019, accounting for more than one-fourth of the U.S. digital therapeutics market, and is estimated to maintain its dominant position throughout the forecast period. This is attributed to high prevalence of diabetes and availability of cost-effective treatment options. However, the obesity segment is expected to witness the fastest CAGR of 22.1% from 2020 to 2027, owing to surge in number of overweight people and easy accessibility of digital therapeutics software applications to help patients in maintaining their proper diets and track physical activities.

The software segment to maintain its dominance by 2027

Based on product, the software segment accounted for more than two-thirds of the U.S. digital therapeutics market in 2019, and is estimated to maintain its dominance in terms of revenue by 2027. Moreover, this segment would portray the highest CAGR of 20.3% during the forecast period. This is attributed to increase in demand to lower healthcare costs and innovative software and apps containing advanced features that help people stay healthy and gain proper treatment. The research also analyzes the devices segment.

For Purchase Enquiry at:

The business to business segment to continue its highest contribution by 2027

Based on sales channel, the business to business segment contributed to nearly two-thirds of the U.S. digital therapeutics market in 2019, and is projected to continue its highest contribution during the forecast period. This is due to rise in number of players in the industry that offer favorable reimbursement policies to employees through their employers in the U.S. However, the business to consumers segment is estimated to manifest the highest CAGR of 19.8% from 2020 to 2027, owing to ease in accessibility & availability of software and smart devices along with rise in demand of digital therapeutic products among patients and caregivers.

Leading market players

Fitbit, Inc. (Twine Health, Inc.)
Livongo Health, Inc.
Medtronic Plc.
Omada Health, Inc.
Pear Therapeutics, Inc.
Proteus Digital Health, Inc.
Resmed, Inc. (Propeller Health)
Voluntis, Inc.
Welldoc, Inc.
Access AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) at:

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Avenue Library Subscription | Request for 14 days free trial of before buying:

Get more information:

Similar Reports:

Phototherapy Apparatus Market – Global Opportunity Analysis and Industry Forecast, 2020–2027

Digital Pathology Market – Global Opportunity Analysis and Industry Forecast, 2019-2026

David Correa
Allied Analytics LLP
+1 800-792-5285
email us here
Visit us on social media:

Source: EIN Presswire

FREE Online Health Education Program About Clinical Research Set for October 1st

International Organizations, Nonprofit Advocates and Local Partners Providing Education and Information on Clinical Research and Role in Health Care

PHILADELPHIA, PA, USA, September 30, 2020 / — Following decades of distrust and misinformation about clinical research and its role in the development of treatments and healthcare, a unique consortium of health educators are coming together on October 1 for a free event to educate the public about clinical research participation.

AWARE for All is a free program that aims to educate and empower the public in making informed decisions about clinical research. Led by the nonprofit, the Center for Information and Study on Clinical Research Participation (CISCRP), and supported by local research teams, advocacy groups, and a consortium of biopharmaceutical and service provider companies, the free online health education event about clinical research will be held Thursday, Oct 1. The event is open to the public and will take place from 4-6pm EDT via a secure online platform.

CISCRP's AWARE for All Philadelphia program comes at a critically important time when public interest in learning about clinical trials is high and the need for study volunteers in all disease conditions – including COVID-19 clinical trials -has increased sharply. In addition, the importance of diversity and inclusion in clinical trials has intensified given the under-representation of minority patients in clinical research and the disproportionately high incidence and severity of COVID-19 cases among minority communities.

"We're really encouraging the general public to attend this important event," said Joan Chambers, Senior Director at CISCRP. "The program will answer a lot of key questions that the public wants to know about the clinical trials process, what to expect as a study volunteer, and the benefits and risks of participation."

The AWARE for All online program on October 1 will feature Dr. Jonathan Jackson from Massachusetts General Hospital and the Harvard Medical School as the keynote speaker. It will include a panel discussion among patients and researchers sharing their real experiences in clinical research. Attendees will have an opportunity to ask questions, participate in two health exercises, and visit a virtual educational health fair connecting with local and national community health advocates and researchers. A virtual theater will also be available presenting educational videos.

"Clinical research awareness is vital to the success of clinical trials," added Dr. Jonathan Jackson, Ph.D., Director of the Community Access, Recruitment, and Engagement (CARE) Research Center. "The success of clinical trials also depends on including a diverse and inclusive group of people representative of those who may receive the new therapy if it is approved for use."

Paulette McDaniels is one clinical research participant and encourages others to do their own research before they decide about joining a clinical trial. She also mentioned you learn more about your own health and body in a clinical research study, and that can help inform the study. "You have to know your own body, so you are aware when a change or something is happening, and you bring it back to your doctor. This is team effort. If you aren't working with your doctors on the team that's doing the study, nobody is going to get anywhere," says McDaniels.

As an African American woman, McDaniels also sees it as her job to help inform medical outcomes for other minorities. "My job as the patient in the study is to actively participate in the research so we an affect everyone for the better," she says.

In addition to broad clinical research topics, some program material and exhibitors will also provide health and clinical trial information specific to the greater Philadelphia area.

One virtual health fair exhibitor is a local Philadelphia organization seeking to better inform clinical research with systematically collected, anecdotal data about what works for various diseases and conditions. Maria Picone is the founder of Trend Community, a digital analytics company that analyzes social media conversations for health outcomes. After her daughter was born with a rare disease with secondary conditions to manage, Picone became interested in medical research. "We're learning what people are doing to manage their diseases, what they need to support their health better, and then report that to help develop new and better treatment options," says Picone.

Supporters of this event include Albert Einstein Healthcare Network, Drexel University College of Medicine, Greenphire, Lazarex Cancer Foundation, National Alliance on Mental Health – Montgomery County chapter, Allergy & Asthma Network, Fox Chase Cancer Center, TREND Community and the AWARE Industry Consortium.

The public is encouraged to register to attend AWARE for All Philadelphia by visiting the Eventbrite page. Please call 877-633-4376 or visit for more information.

The Center for Information and Study on Clinical Research Participation (CISCRP) is a 501(c)(3) non-profit organization dedicated to engaging the public and patients as partners in the clinical research process. CISCRP provides free education and outreach to the general public and patient communities. Visit for more information or to participate in CISCRP's educational initiatives. For additional questions about AWARE for All, contact or call 877-633-4376.

Lena Parsons
Parsons Public Relations Consulting
+1 773-425-0725
email us here

Source: EIN Presswire

Sleep Aids Market to Hit $79,851 Million Globally, At 7.0% CAGR

Sleep Aids Market to Gain a Stronghold During COVID-19 Pandemic Period, Get detailed COVID-19 impact analysis on the Sleep Aids Industry.

NE WIN SIVERS DRIVE, PORTLAND, UNITED STATES, September 30, 2020 / — The sleep aids market size accounted for $49,543 million in 2016 and is estimated to reach $79,851 million by 2023, registering a CAGR of 7.0% from 2017 to 2023. North America is the highest contributor in the sleep aids market; however, Asia-Pacific has witnessed the highest growth rate in 2016.

Download Sample Report with Detailed COVID-19 Impact Analysis at:

Sleep aids in the form of drugs and medical devices are used for the diagnosis and treatment of sleep disorders, such as sleep apnea and sleepwalking. These are expected to improve the quality of sleep for patients with sleep disorders. Sleep disorders could adversely affect human health and cause chronic diseases, such as diabetes and cardiovascular diseases.

Change in lifestyle, stressful working conditions, other issues that interfere with sleep habits, rise in disposable income among the customers, and growth in awareness about the adverse effects of sleep disorder on human health are expected to boost the growth of the sleep aids market. The risk of sleep disorder increases with age and obesity thus, the rise in the geriatric and obese population could increase the prevalence of sleep disorder, which is expected to fuel the market growth. The rise in demand for sleep aids has also lead to an increase in the advancement of technology, which will further open new avenues for market growth. However, the adverse effects of sleep drugs on human health and patent expiration are expected to hamper the market growth.

The mattress & pillows segment was the highest revenue contributor in 2016 and is anticipated to continue this trend during the forecast period. The availability of a variety of products, awareness about the health benefits of quality sleep, and advancement in manufacturing techniques are some of the driving factors for the growth of this segment. Insomnia dominates the sleep aids market and is expected to remain the highest contributor toward the market growth, owing to the presence of a large population base suffering from insomnia.

For Purchase Enquiry at:

In 2015, North America accounted for maximum contribution to the total revenue generated, owing to the high prevalence rate of sleep disorders, the presence of high disposable income, and the high adoption rate of technologically advanced products. However, Asia-Pacific is expected to witness the highest CAGR during the analysis period, attributable to a rise in disposable income, an increase in government initiatives to modernize healthcare infrastructure and rise in healthcare expenditure.

The key companies profiled in the report include

• Koninklijke Philips N.V.
• Merck & Co.
• Sanofi
• eVilbiss Healthcare LLC.
• Pfizer Inc.
• SleepMed Inc.
• Cadwell Laboratories Inc.
• Compumedics Limited
• Natus Medical Incorporated, and
• GlaxoSmithKline plc

Access AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) at:

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Avenue Library Subscription | Request for 14 days free trial of before buying:

Get more information:

Similar Reports:

Bioinformatics Market – Global Opportunity Analysis and Industry Forecast, 2020–2027

STD Testing Market – Global Opportunity Analysis and Industry Forecast, 2019-2026

Oncology/Cancer Drugs Market – Global Opportunity Analysis and Industry Forecast, 2019-2026

Cardiac Biomarkers Market – Global Opportunity Analysis and Industry Forecast, 2019–2026

Pharmaceutical Packaging Market – Global Opportunity Analysis and Industry Forecast, 2019-2026

Prefilled Syringes Market – Global Opportunity Analysis and Industry Forecast, 2019–2026

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Analytics LLP
+1 800-792-5285
email us here
Visit us on social media:

Source: EIN Presswire

Being the Pedestrian in a Hit and Run Accident

Personal Injury Attorneys

The steps you should take if you are a victim of a hit-and-run accident.

Hit-and-run accident cases are hard to navigate. Work with an attorney who will explain your options and help you determine the best course of action.”

— James C. Haggerty

PHILADELPHIA, PENNSYLVANIA, UNITED STATES, September 30, 2020 / — Car accidents don't happen to just those in vehicles; pedestrians walking nearby can fall victim too. According to the Centers for Disease Control and Prevention, 5,977 pedestrians were killed in car accidents in the US in 2017, and around 137,000 pedestrians were injured and treated in hospitals. Pedestrians in the older and younger age brackets tend to be at a higher risk of being hit by a car. However, even when you are following the rules of the road, there are times when a driver’s negligence is the cause of the accident.

All vehicle accidents are bad and usually result in some form of injury, but when the driver just hits a pedestrian walking by and runs away instead of helping the victim, it is inhumane.

Pennsylvania law stipulates that the driver who has caused the accident, intentionally or not, has to stop and wait for medical help to arrive in addition to sharing his or her contact details and other information with the police and the victim. In the case of a hit-and-run accident, you are left without this important information which means the chances of you getting a deserving claim is weakened.

The Steps You Should Take If You Are a Victim of a Hit-and-Run Accident
There are steps you can take to prevent such an accident from occurring. Whenever you are walking alongside a road, even if on the sidewalk, be careful and be alert of your surroundings. Always follow traffic rules and no matter how late you are, always be patient and wait for your turn. Only cross the street when the pedestrian signal is green, and be sure to look both ways before and while crossing.

If you’ve been a victim of a hit-and-run accident, the driver has left the scene without providing their contact information, so you are unable to file a case against him/her. However, this does not mean you have to let go of the case.

When you are first hit, try to gather as much information about the car and driver before he/she flees the scene. This can include the license plate number, the color, make, and model of the car, and any other identifying marks that would help the police catch them. If there are witnesses nearby, they may be able to help fill in the gaps of the accident. Use this information to create a report with the police at the scene. Their report and investigation will be crucial to your case. Most of the time, drivers in such accidents are apprehended.

File a claim with your insurance, and get medical treatment as soon as possible because your well-being is more important than anything else. Then, leave the rest to a trusted car accident lawyer with experience in hit-and-run accident cases. These cases tend to be more complex, and you need to understand all the legal options available.

In case of severe injuries, you will need high-quality medical treatment for a long period of time. The insurance claim may not always suffice, so you may have to research if other options are available. A personal injury lawyer has the expertise on such accidents and will help you to figure out the most viable path for your situation.

The trauma of being in a car accident can take a long time to heal: physically, mentally, and emotionally. If there are grievous injuries, then it could be difficult for you to collect evidence to help your case. An auto accident attorney has handled such cases before, and they will know what can be done to help you most in your situation. Let a personal injury attorney take care of your case while you recover.

If you have been a victim of a hit-and-run case, you already have a lot on your plate. Talk to our expert legal advisors and find out what’s best in your case. Give us a call at (267) 350-6600 or head to our website and receive a free case review.

+++++ Disclaimer+++++ This press release is considered advertising and does not constitute any client-attorney privilege and does not offer any advice or opinion on any legal matter. This release was drafted by Results Driven Marketing, LLC a digital marketing, Public Relations, advertising and content marketing firm located in Philadelphia, PA.

James C. Haggerty
Haggerty, Goldberg, Schleifer, & Kupersmith, P.C.
+ +1 267-350-6600
email us here
Visit us on social media:

Source: EIN Presswire

Whom Can I Sue For Medical Malpractice?

Personal Injury Attorneys

When filing a medical malpractice claim, doctors are most commonly sued. However, pharmacists, nurses, and those that employ them can also be liable.

If your medical provider fails to act where others with comparable training would have, the provider may be liable for the resulting injuries and losses associated with it.”

— James C. Haggerty

PHILADELPHIA, PENNSYLVANIA, UNITED STATES, September 30, 2020 / — If you visited a doctor and were harmed by the line of treatment, you can sue the doctor for medical negligence or malpractice. While doctors are the most commonly sued for medical malpractice, a lawsuit can also be filed against pharmacists, nurses, or other health specialists including the organizations that employ them.

The law permits you to sue for medical malpractice if your well being was in the hands of a medical professional but you were injured due to their negligence. While you may be understandably distressed and disappointed to file the case against the guilty party, you must also be aware of the general rules while suing for medical malpractice.

Common Types of Medical Malpractice
You may have heard of various incidences of medical negligence such as a doctor leaving an operating instrument or a sponge inside the patient's body during an operation. It could also be in the form of failure to inform the patient about the side effects associated with a prescription drug. Most medical malpractice suits fall within these two categories:

Failure to diagnose or prescribing improper treatment
If your doctor incorrectly diagnosed your illness and provided unsuitable treatment, you may sue your doctor for medical malpractice or negligence. You must, however, be able to prove the same in court.

Failure to warn about the risks involved
All doctors are responsible for warning patients of associated risks of medical procedures and/or prescription drugs. The doctor cannot force patients that choose not to be treated to undergo any risky procedure or consume risky medications. You may sue your doctor for medical negligence if the doctor fails to warn you of any known risks associated with the procedure or prescribed drug.

Special Requirements in Medical Malpractice Cases

Statute of limitations
Cases related to medical malpractice or negligence must be brought immediately after the patient discovers the problem. In Pennsylvania, the patient must file a claim within two years of the date in which the malpractice was discovered.

Medical malpractice review panels
You may be required to submit your claim to a malpractice panel for review. After hearing the arguments, the panel of experts would determine whether negligence or malpractice occurred. However, the panel cannot award penalties.

Expert testimony
A qualified expert often strengthens your case and is often a crucial aspect when suing a doctor for malpractice or negligence. Except in some cases, an expert affidavit or testimony is required during these proceedings.

Limits on damage awards
The state of Pennsylvania does not currently have a cap on medical malpractice damages, so an injured patient is free to recover all financial losses including compensation, pain and suffering, and any other losses caused by the malpractice or negligence. However, Pennsylvania does cap punitive damages, but these are rarely awarded in these types of cases.

Basic Requirements for a Claim
You must be able to prove the doctor-patient relationship while suing your doctor for medical negligence or malpractice. Additionally, you must meet the following requirements to prove that medical malpractice occurred:

Negligence of doctor
You can’t sue your doctor if you are unhappy with the treatment or results. In order to sue for malpractice, you must be able to prove your doctor’s negligence in diagnosing the disease or the treatment prescribed. You may be required to prove that the treatment caused you damage or harm. The care or treatment may not be the best, but it must be reasonably acceptable, careful, and skillful.

The majority of the states, including Pennsylvania, require the patient to present a medical expert who can discuss the suitable standard of care by medical representatives. The expert must also be able to prove the defendant’s negligence and deviation from such standard.

Proving the doctor's negligence caused the injury
While it is important to prove that the doctor’s negligence caused the patient injury or harm, it is also very difficult to prove. For instance, a patient dies after being treated for a stroke. In such a case, it might get difficult to prove that the patient died of the doctor's negligence, not of the stroke.

Specific damages
You can’t sue your doctor if you didn’t suffer any damage or harm. However, you may sue your medical provider for the following types of harm:
• Additional medical bills
• Mental distress
• Physical ache
• Lost work and/or earning capacity

Medical malpractice is a very common problem and suing for medical malpractice may be stressful and overwhelming. Contact one of our expert lawyers at (267) 350-6600 if you suspect negligence from your medical practitioner.

+++++ Disclaimer+++++ This press release is considered advertising and does not constitute any client-attorney privilege and does not offer any advice or opinion on any legal matter. This release was drafted by Results Driven Marketing, LLC a digital marketing, Public Relations, advertising, and content marketing firm located in Philadelphia, PA.

James C. Haggerty
Haggerty, Goldberg, Schleifer, & Kupersmith, P.C.
+1 (267) 350-6600
email us here
Visit us on social media:

Source: EIN Presswire

Cardiac Arrhythmia Monitoring Devices Global Market Is Expected To Grow With A CAGR Of 7% In Forecast Period 2018-2026

PUNE, INDIA, INDIA, September 30, 2020 / —  

Cardiac Arrhythmia Monitoring Devices Market – 2018-2026


Cardiac Arrhythmia Monitoring Devices Industry Overview:

 The growing occurrence of heart rhythm disorder represented the incomes worth US$ 5 Bn, in 2018. The growing consumer’s preference towards the continuous heart monitoring to avoid the prevalence of cardiac arrhythmias is principally supporting the development of cardiac arrhythmia monitoring devices market. ~7% CAGR has been anticipated for the Market market more than 2019-2029, which is conspicuously evaluated to be driven by the on-going research and development in the heart monitoring techniques. North America is foreseen to remain the main market for cardiac arrhythmia monitoring devices market during the estimated time frame. Asia Pacific's market for cardiac arrhythmia monitoring devices market is foreseen to witness ~8.5% CAGR through 2029.

Cardiac arrhythmia monitoring devices are extremely useful in tracking the heart function and report any abnormalities in normal function (rhythm). Hence, they do not just help in maintaining a continuous record of heart function but have also proven to be lifesavers due to their ability to report abnormalities in normal heart function, like in the case of a cardiac event.

Get Sample Report PDF >>

Top Key Players Of Cardiac Arrhythmia Monitoring Devices Industry:

Astra Zeneca
Fresenius Se & Co.
Hikma Pharmaceuticals

Extra Insight
The on-going research and development to Open Doors to Multiple Opportunities
At present, Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia worldwide. A large number of people die each year’s owing to the undetected heart rhythm disorder. The continuous monitoring of heart rhythm can detect many arrhythmias for diagnostic testing. In recent years, several types of new and advanced technology have been introduced in heart rhythm monitoring such as wearable technology. Wearable technologies have become an important technology for continuous care and remote monitoring. These wearable devices help to identify the artificial fabrication and prompt ensuing clinical estimation to confirm the diagnosis. Thus, the ongoing innovations and the advancements in the cardiac arrhythmia monitoring devices are anticipated to promote its growth over the forecast years.

Complete Industry Report »

Key Market Trends | Growth | Share | Sale | Revenue | Manufactures | Technology Component

Increasing Use of Telecardiology

In disorders like cardiac arrhythmia, cardiac monitoring is not just essential but is needed continuously. Cardiac arrhythmia is not fully curable and since it is not practical to retain a patient in the hospital for extremely long durations or to ask a patient to visit the hospital every day (that too for several times a day in some cases). The best possible way to continuously monitor the patients suffering from cardiac arrhythmia is through remote patient monitoring by using cardiac arrhythmia monitoring devices. This in technical terms, is referred to as telecardiology. In telecardiology, the patients suffering from cardiac arrhythmia are given a cardiac arrhythmia monitoring device which is then superficially fixed on the chest area of the patient. These devices monitor heart rhythm through a set of two or three electrodes and record any abnormalities in heart function and some of these devices can even autonomously record an abnormality or a cardiac event and alert the healthcare professionals. Most of these devices can be monitored remotely and make it possible to effectively and efficiently monitor the patients suffering from cardiac arrhythmia. As it is extremely convenient to monitor the patients remotely when compared to regular patient visits to hospitals, telecardiology is becoming extremely popular both among the patients and the doctors. For instance, currently more than 5 million cardiac arrhythmia patients are being monitored globally through telecardiology and is expected to grow with double digit growth percentage in the next five years. This huge growth in telecardiology means the increase in demand for cardiac arrhythmia monitoring devices, which will ultimately drive the market for these devices. The other factors, such as ease of use, portability of cardiac arrhythmia monitoring devices, and development of smart cardiac monitors are driving the cardiac arrhythmia monitoring devices market.

Quality Cannot be Controlled by the Devices

Most of the cardiac arrhythmia monitoring devices come with an automatic analysis software, which analyses the signal. But this analysis depends entirely on signal quality, which in turn is dependent on several different factors, such as proper attachment of the electrodes to the patient’s body, electromagnetic disturbance due to other devices in the vicinity, like the smartphones, and other factors, such as muscle tremors. These devices cannot control these factors and often result in a bad quality signal, which results in the wrong analysis by the analysis software. Often, this wrong analysis is considered by patients as the defect in the device itself and this is leading to a loss of faith in these devices. This is ultimately affecting the sales of these devices and is hindering the market. The other factors, such as poor adoption of telemetry technology in emerging markets and the high cost of remote cardiac arrhythmia monitoring are also hindering the market.

United States Leads the Market in North America

In 2017, the United States cardiac arrhythmia monitoring devices market held the largest market share in North America due to the presence of high-quality healthcare systems and increasing prevalence of cardiac diseases in the region. In the Asia-Pacific sector, China and South Korea have been identified as potential emerging markets.

Key Factors Shaping cardiac arrhythmia monitoring devices
The high prevalence of heart rhythm disorder is the key factor that drives the growth in the cardiac arrhythmia monitoring devices market worldwide. The Monitoring of the heart’s rhythm is the major keystone of the diagnosis of cardiac arrhythmias. The several devices are used in the cardiac arrhythmias monitoring and diagnosis that includes ECG, mobile cardiac telemetry, implantable monitors, and Holter monitors. These devices are offers convenient and the faster monitoring that helps to improve treatment outcome. Furthermore, the growing use of arrhythmia monitoring devices in the Atrial fibrillation is escalating the growth of cardiac arrhythmia monitoring devices market.

Continued . . .

Wise Guy Reports
+162 825 80070
email us here

Source: EIN Presswire

Ophthalmic Ultrasound Devices Global Market Is Expected To Grow With A CAGR Of 6.1% In Forecast Period 2018-2026

PUNE, INDIA, INDIA, September 30, 2020 / —  

Ophthalmic Ultrasound Devices Market – 2018-2026


Ophthalmic Ultrasound Devices Industry Overview:

 The global ophthalmic ultrasound devices market size was esteemed at USD 456.4 million of every 2018 and is anticipated to develop at a CAGR of 6.1% by 2026. Developing commonness of ophthalmic diseases, for example, diabetic retinopathy and cataract and regular dispatch of items are among the components driving the market development

Ocular ultrasound keeps on being an integral diagnostic tool in ophthalmology as it has huge applications including representation of posterior eye segment in dense cataract or vitreous hemorrhage conditions. Basic use of ophthalmic ultrasound devices incorporates estimating the central length to decide the intensity of corrective lens, visualizing lens dislocation, distinguishing choroidal melanoma and retinal detachments, and diagnosing other ophthalmic issue.

Developing frequency of way of life and age-related ophthalmic conditions and expanding number of claim to fame eye care centers in creating locales are among the variables expected to lift market request over the gauge time frame. According to WHO, the quantity of individuals experiencing diabetes has expanded to 422 million of every 2014 from 108 million of every 1980. Diabetic retinopathy is seen in one out of three patients and is one of the real reasons for visual deficiency.

The propelling factors for the growth of the ultrasound devices market include the government and private funding for R&D in ultrasound imaging, increasing number of healthcare providers, technological advancements, and increasing incidences of chronic diseases.

The incidences and prevalence of chronic diseases are rapidly increasing all around the world. Currently, affecting more than 14 million people around the world, the prevalence of cancer is becoming a major concern for the healthcare sectors across the world. The demand for ultrasound imaging devices is expected to rise, along with the demand for the early detection of disease and minimization of cost of treating these chronic diseases. This also increases the number of diagnostic imaging procedures. The significant contribution to medical diagnostics and the ease of use have created a huge demand, and therefore, attracted various funding bodies to invest, which is expected to increase in the coming years.

The rising technological advancements supported by the adoption of trusted associations, are expected to boost the market growth. Curtailment in the size of ultrasound devices has given the market a slight boost, if not a significant one. It has given the healthcare facilities a chance to replace old heavy devices with small devices. With the reduction in size of these devices, the problem of storage is solved, enabling the facilities to operate more efficiently with more number of devices.

Get Sample Report PDF >>

Top Key Players Of Ophthalmic Ultrasound Devices Industry:

Ellex Medical
Quantel Medical
Micro Medical Devices
Wuhan Strong Electronics
Escalon Ophthalmics

Scope of the Report

As per the scope of the report, a diagnostic ultrasound, also known as sonography, is an imaging technique that uses high-frequency sound waves to produce images of the different structures inside the body. They are being utilized for the assessment of various conditions in the kidney, liver, and other abdominal conditions. They are also majorly used in chronic diseases, which include health conditions, such as heart disease, asthma, cancer, and diabetes. Therefore, these devices are being utilized as both diagnostic imaging and therapeutic modality, and have a wide range of applications in the medical field.

As indicated by the National Eye Institute, the quantity of individuals experiencing cataract in the U.S. is relied upon to reach around 40 million out of 2030. Medical procedure, the main viable treatment for cataract, is performed simply after ocular ultrasound imaging to decide the intensity of corrective lens. Imaging is additionally done postsurgery to guarantee that lens is superbly set, implying the capability of ophthalmic ultrasound devices.
Ascend in number of activities to improve access to cataract treatment in provincial regions of created just as creating areas is relied upon to build the interest for ophthalmic ultrasound systems.For example, National Program for Control of Blindness (NPCB) is one of the activities concentrated on giving eye care administrations to the underserved patient pool, fortifying of HR in the field of ophthalmology, and advancement of maintainable framework.
In view of versatility, global ophthalmic ultrasound frameworks market is segmented into portable/handheld and standalone devices. Standalone devices held the biggest offer in 2018, attributable to components, for example, simple accessibility, moderateness, and simple taking care of. The prevalence of standalone devices is relied upon to decay over the figure time frame with presentation of cutting edge, precise handheld frameworks.
Space compels in ophthalmologist centers, progressing presentation of portable ocular ultrasound devices with development highlights at affordable valuing, and improving standard of human services the world over are relied upon to help development of this segment. With intense interest for portable devices, real players are offering trade offers on standalone devices, boosting segment development. Subsequently, this segment is relied upon to show quickest development during the gauge time frame.

Complete Industry Report »

Key Market Trends | Growth | Share | Sale | Revenue | Manufactures | Technology Component

3D and 4D ultrasound imaging is the segment under technology that expected to grow fastest during the forecast period

3D and 4D ultrasound imaging take images at various angles, as compared to a single angle by 2D ultrasound. 4D ultrasound has added advantages of visualization and motion. These ultrasounds are likely to experience a substantial growth in the coming years, with the higher adoption of technologically advanced devices for better clinical decisions. Additionally, this segment is anticipated to gain more share and emerge as the fastest-growing segment during the forecast period. The 3D and 4D ultrasound imaging segment is expected to witness a CAGR of 4.27% over the forecast period.

Continued . . .

Wise Guy Reports
+162 825 80070
email us here

Source: EIN Presswire

Artificial Intelligence In Diagnostics Market – Disruptive Global Pandemic Calls for Business Innovations

Global AI In Diagnostics Market was valued at USD 274 Mn in 2019 and is projected to touch USD 2424 Mn by 2027, rising at a CAGR of 31.5% from 2020 to 2027.

LEEDS, WEST YORKSHIRE, UNITED KINGDOM, September 30, 2020 / — Global AI In Diagnostics Market Analysis

Global AI In Diagnostics Market was valued at USD 274 Million in 2019 and is projected to touch USD 2424 Million by 2027, rising at a CAGR of 31.5% from 2020 to 2027.

Key components which are driving the market development include rising demand for lowering diagnostic cost, enhancing affected person care, lowering machine downtime coupled with rising demand for low-cost diagnostic techniques, efficient & environment friendly report analysis, and fast diagnostic information generation. Moreover, developments in AI and deep learning are anticipated to show extra efficient in figuring out illness analysis over the next few years.

Artificial intelligence (AI) refers to creation of distinctive techniques with the assistance of algorithms and software program that may carry out certain duties with out human intervention and instructions. Artificial intelligence includes integration of a number of applied sciences corresponding to machine learning, natural language processing, reasoning, and perception. AI is utilized in diagnostic for approximation of human cognition and evaluation of complicated medical and diagnostic imaging data. Artificial intelligence is primarily utilized in healthcare to research the connection between treatment methods and patient outcomes. AI applications are deployed in medical practices corresponding to diagnostic processes, drug growth, personalized medicines, and affected person monitoring care. For example, AI may assist in medical processes by checking the very important indicators, asking questions, and giving prescriptions to the patients. AI techniques may also be used for alerts and reminders, image interpretation, data retrieval, and remedy planning throughout medical procedures. Deep learning technology is used for image recognition, signal recognition, and data mining and is essentially the most extensively used type of AI technology.

Browse Report Description

Artificial Intelligence functions range from image acquisition, processing to aided reporting, follow-up plan, information storage, data mining, and others. Using machine learning incorporates computational models and algorithms that imitate the structure of the biological neural network in brain, i.e., artificial neural networks (ANNs). Performance wise Deep studying has greater efficiency rate in comparison with traditional machine learning.

Furthermore, AI has quite a few and numerous functions in medical diagnostics, corresponding to image evaluation for tumor detection, video detection for gait problems and fall prediction, biochemical checks corresponding to for diabetes or speech evaluation of emotional state and psychiatric problems. Due to this fact, AI will significantly disrupt the normal model of medical diagnosis.

Global AI In Diagnostics Market Overview

Rising number of government initiatives to encourage healthcare suppliers and different healthcare organizations to undertake AI-based diagnostic applied sciences and rising investments by nonprofit organizations and personal corporations to achieve higher information exchange improved scientific outcomes, and cost reductions are among the main components anticipated to drive the expansion of the marketplace for AI in diagnostics throughout the forecast interval. Furthermore, excessive demand for e-diagnostic providers within the healthcare sector because of increased authorities spending on healthcare is fueling market development.

Moreover, rising demand for lowering diagnostic prices, bettering patient care, and lowering machine downtime is among the components accelerating the utilization of artificial intelligence in diagnostics. Furthermore, rising demand for low-cost diagnostic strategies, efficient and efficient report evaluation, and fast diagnostic information era are few different components anticipated to drive the marketplace for AI in diagnostics. AI-powered gadgets are utilized in emergency medical procedures leading to lowering the time delay between trauma and analysis, thereby resulting in fast interventions and improved patient outcomes.

One other main factor fueling the market development at present is the adoption of this technology by a number of pharmaceutical and biotechnology corporations internationally to expedite vaccine or drug growth processes for COVID-19. Moreover, developments in AI and deep learning are anticipated to show extra efficient in figuring out illness analysis over the following few years.

Nonetheless, greater value for implementation of AI technologies, rise in safety issues, and government guidelines & regulations may hamper the overall market at a world level. Low healthcare access, and shortages of expert human assets are additionally anticipated to negatively affected the expansion within the historic interval.

Request Sample

Global AI In Diagnostics Market: Segmentation Analysis

Global AI In Diagnostics Market by Component

Primarily based on Component, the market is bifurcated into hardware, software and services. Software program section maintain largest share in AI in diagnostic market throughout forecast interval. Many corporations are creating software program options for numerous healthcare functions; that is the important thing issue complementing the expansion of the software program section. The rising demand for AI-powered and cloud-based augmented diagnostic options that assist in rising the diagnostic precision whereas deciphering medical images of a affected person is among the key components driving the section.

Global AI In Diagnostics Market by Technology

Primarily based on Technology, the market is bifurcated into Machine Learning, NLP, Context-Aware Computing, Computer Vision. Machine learning in AI diagnostics market projected to develop at highest CAGR throughout forecast interval. Rising adoption of deep studying in numerous healthcare functions, particularly within the areas of medical imaging, illness diagnostics, and drug discovery, and the usage of completely different sensors and gadgets to trace a affected person’s well being status in real time are supplementing the expansion of the market. Machine/deep learning with the Convolutional Neural Networks (CNNs) has not too long ago been gaining big consideration owing to its high-end efficiency in picture recognition.

Global AI In Diagnostics Market by Diagnosis Type

Primarily based on Diagnosis Type, the market is segmented into Radiology, Oncology, Neurology, Cardiology, Chest & Lungs, Pathology and Others. In 2019, neurology held a largest market share whereas radiology is predicted to be the quickest rising section over the forecast interval owing to the rising growth of AI-based software program available for diagnostic imaging. The neurology accounts for largest variety of regulatory approvals of the overall AI-based medical diagnostics platform.

Request Discount

Alex Jones
Research Report
+44 20 3769 3786
email us here

Source: EIN Presswire

Trupti Sarang Featured in Exclusive Interview

In a recent interview, Trupti Sarang spoke about her career as a clinical pharmacist.

AUSTIN, TEXAS, UNITED STATES, September 30, 2020 / — Trupti Sarang was recently featured in a one-on-one interview with Thrive Global. She shared what she has learned throughout her career as a clinical pharmacist and spoke about motivation, inspiration, and her love for nutrition.

With 20 years of experience as a clinical pharmacist working in a hospital setting, Trupti Sarang aims to educate others on the limitations of modern medicine and presents alternatives to consider through her website.

In the interview, Pharmacist Trupti Sarang shared that she decided to create her own website to empower others by providing them with knowledge about nutrition, herbs, and yoga in order to reduce the risk of chronic illnesses. She hopes to help patients find better solutions to lead a healthy lifestyle.

Ms. Sarang further explained what she respects most about her industry.

“I love working as a clinical pharmacist and the way I am able to help patients. What I love about my industry is the collaboration, dedication, and teamwork that takes place around the clock to help our sick patients,” she said.

She also shared her biggest accomplishment.

“My biggest accomplishment has been my own personal journey in unraveling so many truths about medications and chronic diseases, and the problems in the medical industry, “ said Trupti Sarang.

“I understand the urgency for change in our healthcare system. I have never given up looking for the facts and have always had an innate curiosity to find the truth about what is safe for patients.”

For more information, visit:

About Trupti Sarang

Trupti Sarang of Austin, Texas, is a clinical pharmacist with 20 years of experience working in a hospital setting. She attended the University of Texas and earned a Bachelor of Arts in English with a minor in Chemistry. She went on to receive a Bachelor or Science in Pharmacy. She completed her Doctorate in Pharmacy from the Massachusetts College of Pharmacy and Health Sciences in Boston. Most recently, Trupti Sarang launched a website to provide information and help patients reduce the risk of chronic diseases through nutrition, yoga, and alternative medicine.

Trupti Sarang
Clinical Pharmacist
+1 210-219-0350
email us here

Source: EIN Presswire

UC Berkeley and Bitmark launch Autonomy app as part of the school's COVID-19 Safe Campus Initiative

Autonomy will be released publicly to the city of Berkeley

Bitmark's digital rights protocol allows study participants to control their personal data.

Autonomy may help participants stay engaged by keeping them informed about the community around them without sacrificing personal privacy.”

— Shelley Facente

BERKELEY, CA, USA, September 30, 2020 / — As part of UC Berkeley's Safe Campus Initiative, the university and Bitmark Inc. have partnered to launch Autonomy, a public health app that helps users understand how their local community is managing with COVID-19. In the process, Autonomy enables participants to control their rights to personal data submitted to the app, creating a safe privacy-first environment in which participants always opt-in.

The Safe Campus initiative is UC Berkeley's program to establish a system to keep the campus and surrounding communities safe to facilitate the eventual ramp-up of on-campus activities at the university. The study is led by a team of researchers at the UC Berkeley School of Public Health—in partnership with University Health Services; the Innovative Genomics Institute; the Division of Computing, Data Science and Society; and the City of Berkeley health department.

Shelley Facente, the lead graduate student researcher for the Berkeley Safe Campus Initiative, said, "We are excited to make Autonomy available as an optional companion app for the initiative. Autonomy may help participants stay engaged by keeping them informed about the community around them without sacrificing personal privacy."

Safe Campus is estimating the incidence of new infections of SARS-CoV-2 (the virus that causes COVID-19); discovering who seems more likely to develop infection and why; developing strategies for how best to mitigate this risk; and allowing the campus to create effective systems to track potential infections. The ultimate goal of the study is to learn how to effectively prevent and control ongoing transmission as the school ramps up on-campus activities.

The Autonomy app completes the engagement loop for study participants: they contribute symptom and behavior data to the study and receive feedback through aggregated study data from the app. Autonomy also lets participants rate and review COVID-19 safety practices among local restaurants, café's, bookstores, and other shops.

"Everyone understands that sharing private health information at an aggregate level can help stop the spread of COVID-19. However, sacrificing personal privacy should never be part of the bargain. UC Berkeley was the perfect partner with whom to launch Autonomy because of their care for individuals' rights. We are excited to not only be part of this initiative with a world-class institution, but to also activate the local community in helping everyone get better in this pandemic," said Sean Moss-Pultz, Bitmark CEO and co-founder.

After the study concludes on September 30th, the app will be opened to all Berkeley residents and accessible as a web app on all Google Android and Apple iPhone devices, giving everyone access to the world-class public-health technology pioneered by UC Berkeley and Bitmark. Try here.

Headquartered in Taiwan, Bitmark started Autonomy after seeing the country respond successfully to COVID-19 through trusted collaboration between the local government and its citizens. Bitmark sought to bring this model of public health to the rest of the world and is launching Autonomy first with UC Berkeley to strengthen the collaboration between the university and its students, faculty, and staff.

The app, including its privacy and data practices, was fully reviewed and approved by UC Berkeley's Committee for the Protection of Human Subjects. Using Bitmark's digital rights protocol, participants can read, export, and delete their data from the Autonomy app at any time. Participants control their rights in Autonomy without the need of third parties acting as gatekeepers, including Bitmark Inc. – Bitmark's rights protocol operates decentralized through blockchain.

About UC Berkeley

UC Berkeley is a top-ranked public research university, and the oldest campus of the University of California system. It is known for everything from its Nobel Prize-winning faculty (8 of the current faculty members have this prestigious honor) to its role in birthing the Free Speech Movement to its commitment to a diverse student body, with 23% of incoming freshmen being first generation college students.

To learn more about the Safe Campus initiative

About Bitmark

Bitmark's mission is to make data control accessible to everyone. Working across essential services of public health, life sciences, entertainment, and digital identity, Bitmark makes tools for individuals and organizations that extend the Bitmark rights protocol to their specific needs. Premiere institutions partnering with Bitmark include UC Berkeley, Pfizer, and KKBOX. Selected as a Top 100 Technology Pioneer in 2020 by the World Economic Forum, Bitmark is co-founded by serial entrepreneur Sean Moss-Pultz and backed by leading international institutional investors and the government of Taiwan.

Autonomy will be released publicly to the city of Berkeley on September 30th:

Learn more about our work in #digitalrights

Michael Nguyen
Bitmark Inc.
email us here
+1 408-239-6006

Source: EIN Presswire